InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$17.50−2.37 (-11.93%)
Close on Nov 17, 2026Market cap $96.14MP/E –Yield –
InMed Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
InMed Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$7.86M. For fiscal 2026 it was -$8.64M. The highest annual figure on record is -$6.99M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$8.64M | – |
| FY2025 | Jun 30, 2025 | -$8.10M | – |
| FY2024 | Jun 30, 2024 | -$6.99M | – |
| FY2023 | Jun 30, 2023 | -$7.28M | – |
| FY2022 | Jun 30, 2022 | -$15.58M | – |
| FY2021 | Jun 30, 2021 | -$9.79M | – |
| FY2020 | Jun 30, 2020 | -$7.37M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$1.14M | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$2.96M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$1.70M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$2.05M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$1.93M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$2.11M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$1.66M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$2.50M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$1.83M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$1.03M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$1.93M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$1.85M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$2.17M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$657.93K | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$1.66M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$2.71M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$2.26M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$4.05M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$5.35M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$3.53M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$2.65M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$2.01M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$4.61M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$1.80M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$1.37M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$1.40M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$1.52M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$2.09M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$2.37M | – |
See a number that looks wrong?